Khan SU, Khan MU, Valavoor S, et al. Association of lowering apolipoprotein B with mortality and cardiovascular outcomes across various lipid lowering therapies: A systematic review and meta-analysis. Eur J Prev Cardiol. 2020; 27: 1255–1268.
2.
LangloisMRChapmanMJCobbaertC, et al.European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Joint Consensus Initiative. Quantifying atherogenic lipoproteins: Current and future challenges in the era of personalized medicine and very low concentrations of LDL cholesterol. A Consensus Statement from EAS and EFLM. Clin Chem2018; 64: 1006–1033.
3.
HorvathARLordSJSt. JohnA, et al.the Test Evaluation Working Group of the European Federation of Clinical Chemistry and Laboratory Medicine. From biomarkers to medical tests: The changing landscape of test evaluation. Clin Chim Acta2014; 427: 49–57.
4.
ColeTGContoisJHCsakoC, et al.Association of apolipoprotein B and nuclear magnetic resonance spectroscopy-derived LDL particle number with outcomes in 25 clinical studies: Assessment by the AACC Lipoprotein and Vascular Diseases Division Working Group on Best Practices. Clin Chem2013; 59: 752–770.
5.
SnidermanADWilliamsKContoisJH, et al.A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes2011; 4: 337–345.
6.
BoekholdtSMArsenaultBJMoraS, et al.Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: A meta-analysis. JAMA2012; 307: 1302–1309.
7.
RobinsonJGWangSJacobsonTA. Meta-analysis of comparison of effectiveness of lowering apolipoprotein B versus low-density lipoprotein cholesterol and non high-density lipoprotein cholesterol for cardiovascular risk reduction in randomized trials. Am J Cardiol2012; 110: 1468–1476.
8.
ThanassoulisGWilliamsKYeK, et al.Relations of change in plasma levels of LDL-C, non-HDL-C and apoB with risk reduction from statin therapy: A meta-analysis of randomized trials. J Am Heart Assoc2014; 3: e000759–e000759.
9.
MoraSBuringJERidkerPM. Discordance of low-density lipoprotein (LDL) cholesterol with alternative LDL-related measures and future coronary events. Circulation2014; 129: 553–561.
10.
PletcherMJPignoneM. Evaluating the clinical utility of a biomarker. A review of methods for estimating health impact. Circulation2011; 123: 1116–1124.
